Prospects of genetic knowledge outfit 23andMe could also be at larger danger than they understand, suggests a New York Instances story that argues the corporate’s woes could possibly be short-lived in comparison with the longer-term threats probably dealing with these roughly 15 million folks if 23andMe can’t proceed as a going concern.
Actually, with every passing day, the hope of founder and CEO Anne Wojcicki to show round 23andMe appears additional out of attain. The corporate, valued at $6 billion when it went public in 2021, is now valued at $150 million. It’s poised to be delisted subsequent month. Press tales aren’t serving to. (Would you purchase a package?)
The corporate says it stays dedicated to “comply with legal guidelines that regulate the information we gather,” but when in some unspecified time in the future very quickly it might probably’t, that is worrisome, says a Yale biomedical professor who notes to the Instances that hacked bank cards might be changed; a genome can not. In the meantime, he says, the tech that analyzes genomes is advancing. Likelihood is it is going to grow to be extra revealing, too.